BTK and mantle cell lymphoma: TRANSCEND NHL 001 was a seamless design study which evaluated the safety and efficacy of liso-cel in patients with relapsed or refractory large B-cell lymphomas and included a MCL cohort of patients after two prior lines of therapy including a BTK inhibitor, an alkylator, and an anti-CD20 monoclonal antibody (24).